Interpreting the right heart catheterization (RHC) procedure is important for painting an accurate and realistic picture of your patient’s clinical status. This course delivers key details of assessing patients with congenital heart diseases, as well as insights on the evaluation of left heart disease using the RHC procedure. Understanding and deciphering prognostic outcomes and the relationship between RHC variables are also discussed. Plus, learn how to appropriately use RHC for a follow-up and examine the contraindications of the RHC procedure.
Interpretation of the Right Heart Catheterization Procedure
Evaluating Potential CHD Patients
Target Audience
This activity has been designed to meet the educational needs of Cardiologists and Cardiology Residents, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with (Insert Primary Therapeutic Area).
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Define the relationship between RHC variables and associated prognostic outcomes.
- Understand approrpiateness of using RHC as a follow up.
- Implement stratergies to effectively evaluate pateinst with CHD and left heart disease.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.25 contact hours/0.125 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-059-H01-P . This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Vallerie V. McLaughlin, MD, FACC, FAHA
Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, University of Michigan Medical Group
Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Aerovate, Altavant, Goassamer-Bio, Janssen, Merck, Sonovie
Consulting Fees: Aerami, Aerovate, Altavant, Caremark, LLC, Corvista, Gossamer-Bio, Janssen, Merck, United TherapeuticsFaculty:
Richard Krasuski, MD
Professor of Medicine and Pediatrics
Director, Adult Congenital Heart Disease Center
Director, Hemodynamic Research
Director, Interventional CTEPH Program
Duke University Medical Center
Durham, NCDr. Krasuski has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Actelion/Janssen, Artivion, Adult Congenital Heart Association. Corvia, Edwards Lifesciences, Medtronic.
Consulting Fees: Actelion/Janssen, Bayer, W.L. Gore, Medtronic, Neptune Medical.Victor M. Moles, MD
Clinical Assistant Professor
Associate Director, Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MIDr. Moles has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Acceleron Pharma (Merck), Janssen Pharmaceuticals.
Consulting Fees: United Therapeutics.Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Tim Person has nothing to disclose.
- Prerna Poojary, PhD, has nothing to disclose.
- Susan Diaz has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC
Commercial Support
This activity is supported by an independent educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medical Masterclass, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date: